Navigation Links
Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs

Can a common virus boost the cancer-killing abilities of existing cancer drugs? A preclinical study presented// at this year’s EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Prague, Czech Republic concluded that the answer is “yes.” These findings may lead to more effective treatment options for patients suffering from non-small cell lung cancer (NSCLC), a disease in which malignant (cancer) cells form in the tissues of the lung.

The research focused on work conducted by SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute (NCI). The NCI tested the Respiratory Enteric Orphan virus, or reovirus, a non-disease causing virus in combination with a number of widely used chemotherapy drugs. In general, the combination of reovirus with cisplatin, gemcitabine, mitomycin or vinblastine was found to be more effective against NSCLC cell lines sensitive to anti-cancer drugs than each treatment used on its own. The study used REOLYSIN?, Oncolytics Biotech's proprietary formulation of the human reovirus, that has been demonstrated to replicate specifically in and kill tumor cells with activated Ras pathways (uncontrollable growth signals).

Of particular interest to the researchers, the combination of reovirus and paclitaxel, a common chemotherapy drug, was uniformly synergistic in all six cell lines examined, including in those with high-level resistance to paclitaxel or reovirus. The data suggest that the combination of reovirus and paclitaxel may help in promoting cell-death signaling, resulting in a more efficient and synergistic anti-cancer effect against these cell lines than using each agent on its own.

"Data from the NCI and other investigators examining various co-therapies with REOLYSIN is providing Oncolytics with the rationale for its planned combination clinical trial program," said Dr. Matt Coffey, the Chief Scientific Officer at Oncolytics. "This research suggests that REOLYSIN can be combined with many existing therapies that are currently broadly used in the treatment of cancer patients."

Currently, REOLYSIN is being used in Phase I and Phase I/II human clinical trials in the U.S. and the U.K. and the treatment has recently been approved for use in a Phase II trial in the U.K. for various advanced or metastatic cancers. The treatment appears to be well-tolerated by patients, and anti-tumor effects have been reported in all trials reported on to date. The Company plans to initiate human trials with REOLYSIN and various chemotherapies over the next year.

About 85% of all lung cancers are classified as the non-small cell type. Lung cancer is the leading cause of cancer death for both men and women. More people die of lung cancer than of colon, breast, and prostate cancers combined.

Source-Newswise
SM
'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: